Recent developments on the role of mitochondria in poly(ADP-ribose) polymerase inhibition.
Curr Med Chem
; 10(24): 2669-78, 2003 Dec.
Article
en En
| MEDLINE
| ID: mdl-14529457
Numerous pathophysiological disorders involve some element of oxidative stress and bioenergetic deficit. Poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors have been used recently as a promising new therapeutic strategy aimed at halting the bioenergetic decline associated with oxidative brain insults and other conditions. PARP-1 uses NAD+ as a substrate and is activated during stressful circumstances, mainly in the nucleus. PARP-1 inhibitors are well known for blocking the excessive consumption of NAD+, thereby preserving energy metabolism. But what is the role of mitochondria in this process? Recent investigations have begun to focus on whether mitochondrial function can also be preserved by PARP-1 inhibitors. This review will present some of the latest mechanistic evidence documenting the potential involvement of PARP-1 inhibitors in protecting mitochondrial function and preventing necrosis, apoptosis and mitochondrial calcium cycling.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Apoptosis
/
Inhibidores Enzimáticos
/
Inhibidores de Poli(ADP-Ribosa) Polimerasas
/
Mitocondrias
/
NAD
Límite:
Animals
/
Humans
Idioma:
En
Revista:
Curr Med Chem
Asunto de la revista:
QUIMICA
Año:
2003
Tipo del documento:
Article
País de afiliación:
Estados Unidos
Pais de publicación:
Emiratos Árabes Unidos